Welcome to our dedicated page for APOLLOMICS news (Ticker: APLMW), a resource for investors and traders seeking the latest updates and insights on APOLLOMICS stock.
Apollomics Inc. develops clinical-stage oncology therapies for difficult-to-treat and treatment-resistant cancers. Company news centers on vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer and other tumors with c-Met alterations, along with broader pipeline work in targeted therapy and immuno-oncology.
Recurring updates also cover financial results, clinical-development spending, development and commercialization arrangements, bridge and private financings, Nasdaq listing compliance, board and committee changes, litigation resolution, and operating-continuity matters tied to the company’s biotechnology development model.
Summary not available.
Summary not available.
Apollomics Inc. (Nasdaq: APLM, APLMW) announced that Co-Founder and President, Sanjeev Redkar, will present at the 23rd Annual R. Bryan Miller Symposium on April 14, 2023, at UC Davis. Dr. Redkar's talk, titled 'The HGF/cMet Pathway in Cancer – Early Development to Clinical Evidence', will highlight the significance of the HGF/cMet pathway in cancer progression and treatment resistance. This pathway is crucial due to its association with gene mutations that drive tumor growth. Apollomics is advancing APL-101, a selective c-Met inhibitor aimed at treating non-small cell lung cancer and brain tumors. Additional notable speakers include Paula T. Hammond from MIT and David R. Liu from Harvard. Details about the symposium and speaker schedule are available on the UC Davis site.
Apollomics Inc. has completed its business combination with Maxpro Capital Acquisition Corp., allowing its Class A ordinary shares and public warrants to start trading on the Nasdaq Capital Market under the ticker symbols APLM and APLMW as of March 30, 2023. The deal, approved by Maxpro’s shareholders, raised $23.65 million through a private investment in public equity (PIPE) financing, enhancing Apollomics' capacity to develop its oncology pipeline, which includes nine drug candidates. The company aims to address treatment-resistant cancers and expects critical clinical trial results this year that could support regulatory filings.